Literature DB >> 10369079

Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas.

A Sierra1, X Castellsague, A Escobedo, A Moreno, T Drudis, A Fabra.   

Abstract

The overexpression of Bcl-2, an anti-apoptotic oncogene, identifies human T1 breast cancer patients who have an increased risk of lymph-node metastasis. We examined in these patients (n = 142) whether the c-Myc oncogene influences metastatic progression in conjunction or not with Bcl-2 expression and the loss of apoptosis in tumors. The association between Bcl-2 and lymph-node metastasis was only significant when c-Myc was concomitantly expressed (chi2 test, p = 0.008). Moreover, very large associations (pOR = 6.4) between c-Myc and lymph-node metastasis were observed among Bcl-2 positive tumors and tumors with loss of apoptosis (pOR = 8.4). In contrast, the metastatic advantage linked to Bcl-2 was decreased (pOR = 2) when c-Myc was not coexpressed. It is concluded that the synergism between Bcl-2 and c-Myc oncogenes may promote metastasis in breast tumors, linked to loss of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369079     DOI: 10.1023/a:1006120006471

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

Review 1.  The ROCK signaling and breast cancer metastasis.

Authors:  Sijin Liu
Journal:  Mol Biol Rep       Date:  2010-07-03       Impact factor: 2.316

2.  Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice.

Authors:  L Hou; Y Li; Y H Jia; B Wang; Y Xin; M Y Ling; S Lü
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma.

Authors:  Dongli Liu; Lili Dong; Yang Liu; Duo Wen; Dongmei Gao; Huichuan Sun; Jia Fan; Weizhong Wu
Journal:  Tumour Biol       Date:  2015-11-06

4.  Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.

Authors:  Rosalyn D Ferguson; Ruslan Novosyadlyy; Yvonne Fierz; Nyosha Alikhani; Hui Sun; Shoshana Yakar; Derek Leroith
Journal:  Breast Cancer Res       Date:  2012-01-07       Impact factor: 6.466

5.  Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions.

Authors:  Z Protrka; S Arsenijevic; A Dimitrijevic; S Mitrovic; V Stankovic; M Milosavljevic; T Kastratovic; J Djuric
Journal:  Eur J Histochem       Date:  2011-03-16       Impact factor: 3.188

6.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

Authors:  Dai Horiuchi; Leonard Kusdra; Noelle E Huskey; Sanjay Chandriani; Marc E Lenburg; Ana Maria Gonzalez-Angulo; Katelyn J Creasman; Alexey V Bazarov; James W Smyth; Sarah E Davis; Paul Yaswen; Gordon B Mills; Laura J Esserman; Andrei Goga
Journal:  J Exp Med       Date:  2012-03-19       Impact factor: 14.307

7.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.

Authors:  S L Deming; S J Nass; R B Dickson; B J Trock
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

8.  Bcl-2 and c-Myc expression in oral dysplasia and oral squamous cell carcinoma: An immunohistochemical study to assess tumor progression.

Authors:  N Pallavi; Govind Raj K Nalabolu; Santhosh Kumar S Hiremath
Journal:  J Oral Maxillofac Pathol       Date:  2018 Sep-Dec

9.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Authors:  Andrew R Green; Mohammed A Aleskandarany; Devika Agarwal; Somaia Elsheikh; Christopher C Nolan; Maria Diez-Rodriguez; R Douglas Macmillan; Graham R Ball; Carlos Caldas; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.